Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France
- Dexcom ONE expands access to half a million more people with diabetes in France
- Dexcom ONE shown to improve time-in-range significantly more than Flash Glucose Monitoring
- Dexcom real-time CGM clinically proven to lower HbA1C, reduce hyper- and hypoglycemia, and increase time in range
- None.
Dexcom’s announcement brings the company’s highly researched and studied, real-time CGM technology to half a million more people with diabetes in
The proven accuracy of Dexcom ONE1# allows people to make confident treatment decisions in real-time, without scanning, and as a real-time CGM with alerts, is shown to improve time-in-range significantly more than Flash Glucose Monitoring (isCGM)2§.
“We believe this is truly exciting news for people living with diabetes in France,” said Gérald Zammit, Country Director of Dexcom France. "Access to Dexcom real-time CGM sensors is now available to those who live with diabetes, who aren’t necessarily seen as ‘high risk’, but who can still greatly benefit from it. The launch of Dexcom ONE in
Dexcom real-time CGM use is clinically proven to lower HbA1C, reduce hyper- and hypoglycaemia, and increase time in range3-5.
The launch of Dexcom ONE in
§ Results obtained with an rt-CGM with alerts, similar to Dexcom ONE, and compared to Freestyle Libre 1.
# Results obtained with Dexcom G6, which uses the same applicator and sensor (and algorithm) as Dexcom ONE
1 Shah VN, et al. Diabetes Technol Ther. 2018;20(6):428-433. 2 Haskova et al. Diabetes Care. 2020;43(11):2744-2750. 3 Beck, RW, et al. JAMA. 2017;317(4):371-378. 4 Welsh, JB et al. Diabetes Technol Ther. 2019;21(3):128-132. 5. Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911959810/en/
Gemma McDonald
EMEA PR Manager
gemma.mcdonald@dexcom.com
James McIntosh
Global PR Director
james.mcintosh@dexcom.com
Source: DexCom, Inc.